Johns Hopkins

 

Insights from 2023 ASH Annual Meeting
A

ASH 2023 Insights: "A Comparison of HMAs Combined With Ivosidenib or Venetoclax in Newly Diagnosed Patients With IDH1mut AML - A RWE Study"

By Insights from 2023 ASH Annual Meeting FEATURING Alexander Ambinder
By Insights from 2023 ASH Annual Meeting FEATURING Alexander Ambinder
50 views
December 19, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

18:17
Exelixis

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Feat. K. Hanna, J. Strauss

Featured Video

13:36
Exelixis

Hypothetical Patient Case: Hepatocellular Carcinoma and Consideratio…

Feat. J. Gutierrez, J. Strauss
Videos
07:41

New

Impact of Neoadjuvant IO on Recurrence-Free Survival in High-Risk Lo…

Johns Hopkins

M. Nakazawa

42 views
15:57

ASCO® 2024 Summary: "Treatment Strategies and QoL Impact in mCRPC - …

2024 ASCO® Annual Meeting Insights Hub

C. Paller

170 views
11:47

Current Evidence for Frontline Systematic Treatment in Advanced HCC

Johns Hopkins

M. Baretti

272 views
08:11

ASH 2023 Insights: "A Comparison of HMAs Combined With Ivosidenib or…

Insights from 2023 ASH Annual Meeting

A. Ambinder

50 views
13:15

Output From the National MDS Study: Utility of Targeted Gene Sequenc…

Johns Hopkins

A. DeZern

205 views
16:27

Targeting BRAF-Altered Glioma in Adults

Johns Hopkins

K. Schreck

454 views
15:49

Severe Aplastic Anemia: What's on the Horizon?

Johns Hopkins

A. DeZern

557 views
09:23

Advancements in Systemic Therapy for Advanced HCC: Where Are We Going

Johns Hopkins

M. Yarchoan

670 views
34:01

Latest Treatment Strategies and Standard of Care for Pancreatic Canc…

MedNews Week

M. Pishvaian

629 views
21:21

KRASG12C Mutation in NSCLC: Current Data and Future Directions

Johns Hopkins

S. Rosner

448 views